Exhibit 99.2
Consent to be Named as a Director Nominee
In connection with the filing by Pieris Pharmaceuticals, Inc. (the “Company”) of the Registration Statement on Form S-4 with the Securities and Exchange Commission under the Securities Act of 1933, as amended (the “Securities Act”), I hereby consent, pursuant to Rule 438 of the Securities Act, to being named in the Registration Statement and any and all amendments and supplements thereto as a person who has agreed to serve as a director of the Company following its merger with Palvella Therapeutics, Inc. (which shall be known as Palvella Therapeutics, Inc.) as described in the Registration Statement. I also consent to the filing of this consent as an exhibit to such Registration Statement and any amendments thereto.
Dated: August 9, 2024 | /s/ Wesley H. Kaupinen |
Name: Wesley H. Kaupinen |